- Ono Pharma’s operating income for the first quarter is 30.69 billion yen, a 26% drop compared to last year and lower than the estimate of 32.84 billion yen.
- Net income stands at 24.79 billion yen, a decrease of 22% year-over-year, missing the estimate of 25.16 billion yen.
- Net sales are recorded at 117.68 billion yen, which is a 2% decline from the previous year but exceeds the estimate of 112.43 billion yen.
- For the fiscal year 2025, Ono Pharma maintains its forecast for operating income at 122.00 billion yen, higher than the estimate of 112.21 billion yen.
- The company also holds its forecast for net income at 91.00 billion yen, surpassing the estimate of 87.02 billion yen.
- Sales forecasts for 2025 stand at 450.00 billion yen, which is lower than the estimate of 476.9 billion yen.
- Dividend per share for 2025 is projected at 80.00 yen, slightly above the estimate of 79.17 yen.
- Analyst recommendations include 3 buys, 6 holds, and 5 sells.
Ono Pharmaceutical on Smartkarma
Analyst coverage on Ono Pharmaceutical by Tina Banerjee on Smartkarma indicates a bearish sentiment regarding the company’s recent acquisition of Deciphera Pharmaceuticals. The headline, “Ono Pharmaceutical (4528 JP): Deciphera Acquisition Will Not Bring Immediate Respite,” highlights concerns about the $2.4 billion acquisition, which is expected to be completed in Q2FY25. Banerjee’s analysis suggests that while Ono may benefit from the acquisition in FY27, in the short term, it may not address the company’s revenue loss issues. Additionally, the costly nature of the deal and the potential earnings dilution for Ono are identified as significant hurdles.
A look at Ono Pharmaceutical Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Ono Pharmaceutical Co., Ltd. has a promising long-term outlook based on the Smartkarma Smart Scores. With a strong score of 5 in Dividend, the company is well-positioned to provide consistent returns to its investors over time. Additionally, Ono Pharma scores 4 in Growth and Resilience, indicating its potential for sustainable expansion and ability to weather market challenges.
The company’s focus on prescription drug research and development aligns with its overall score of 3 in Value. While the Momentum score of 3 suggests a steady trajectory, the higher scores in Dividend, Growth, and Resilience demonstrate Ono Pharmaceutical‘s solid foundation and potential for long-term success in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
